Identification of chemical compounds that can increase the expression of Dock3, or otherwise reduce the surface expression of NR2D, might have therapeutic benefit for the treatment of neurodegenerative disorders such as Alzheimer’s disease and glaucoma. Here, DOCK3 is linked to early-onset autosomal dominant Alzheimer disease.